Danying Cai

Jackson Laboratory — United States

Medicine · Health Sciences

15h-index1.2kcitations59works0.52yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(13), Monoclonal and Polyclonal Antibodies Research(10), Plant Reproductive Biology(10), Tryptophan and brain disorders(9), Chromosomal and Genetic Variations(8)

Publications59 total

Deciphering the genetic and molecular regulatory mechanisms of the environmental-induced fruit semi-russeting in pear: A review
Scientia Horticulturae·2024Open Access
Abstract 4014: Humanized mouse model to assess PBMC donor derived autologous CD19 CAR Ts for efficacy against Raji tumors and related cytokine release
Cancer Research·2024· 1 cited
Simultaneous evaluation of treatment efficacy and toxicity for bispecific T‐cell engager therapeutics in a humanized mouse model
The FASEB Journal·2023· 14 citedOpen Access
Abstract 4150: Novel preclinical model for the evaluation of cytokine release syndrome in response to CD19xCD3 bispecific antibody in humanized mice
Cancer Research·2023· 1 cited
Abstract 6354: A new tumor-bearing humanized mouse model to evaluate the efficacy of bispecific T cell engager and monoclonal checkpoint antibodies
Cancer Research·2023· 1 cited
Data from Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy
2023Open Access
Table S2 from Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy
2023Open Access
Table S1, Table S3, Figures S1-S8 from Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy
2023Open Access
Table S2 from Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy
2023Open Access
Table S1, Table S3, Figures S1-S8 from Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy
2023Open Access
Supplementary Methods from Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy
2023Open Access
Supplementary Methods from Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy
2023Open Access
Data from Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy
2023Open Access
1250 A novel in vivo PBMC humanized mouse platform for long-term analysis of efficacy and toxicity of T cell-based immunotherapy drugs
Regular and Young Investigator Award Abstracts·2022Open Access
Solving the regulation puzzle of periderm development using advances in fruit skin
Frontiers in Plant Science·2022· 2 citedOpen Access
Abstract 2049: A novel, rapid, sensitive, and reproducible <i>in vivo</i> platform to assess efficacy and toxicity of bispecific antibodies
Cancer Research·2022
Abstract 1338: Humanized mouse model for in vivo evaluation of bispecific antibody efficacy
Cancer Research·2022
Abstract 2816: A novel <i>in vivo</i> model to simultaneously assess efficacy and toxicity of chimeric antigen receptor T-cell immunotherapy
Cancer Research·2022
Abstract 2875: Development of a new tumor-bearing humanized mouse model to evaluate the efficacy and toxicity of bispecific T cell engagers
Cancer Research·2022
Validation of a clinically relevant humanized mouse model for the safety assessment of 4-1BB agonists utomilumab and urelumab.
Journal of Clinical Oncology·2022· 2 cited
page 1 of 3Next →

Frequent Co-authors

James Keck(22), Mingshan Cheng(16), Yuanwen Teng(15), Li‐Chin Yao(13), Leonard D. Shultz(8), Xiaoyan Zheng(8), Yuezhi Wang(7), Meisong Dai(7), Zebin Shi(7), Michael A. Brehm(6), Shuang Jiang(6), Jing Jiao(6), Dale L. Greiner(5), Grégory Driessens(5), Derek W. Bartlett(5), Sandra Cauwenberghs(5), Stefano Crosignani(5), Deepak Dalvie(5), Sofie Denies(5), Christopher P. Dillon(5)